Definition, Meaning & Anagrams | English word KRAS


KRAS

Definitions of KRAS

  1. plural of KRA.

7

Number of letters

4

Is palindrome

No

5
AS
KR
KRA
RA
RAS

29

16

56

41
AK
AKR
AKS
AR
ARK
ARS
AS
ASK
ASR
KA
KAR

Examples of Using KRAS in a Sentence

  • The first two Ras genes, HRAS and KRAS, were identified from studies of two cancer-causing viruses, the Harvey sarcoma virus and Kirsten sarcoma virus, by Edward M.
  • While EAG had gone bankrupt, HollandExel was purchased by TUI which renamed it Arkefly, making it the Dutch inhouse charter airline for Arke, Holland International and Kras Vakanties.
  • Panitumumab was approved by the European Medicines Agency (EMEA) in 2007, and by Health Canada in 2008, for "the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".
  • As of 2006, KRAS mutation was predictive of a very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer.
  • The home games of CS Kras, a team that plays in Terza Categoria (the lowest in Italy), are played on the Repen pitch.
  • The mammalian Ras gene family consists of the Harvey and Kirsten Ras genes (HRAS and KRAS), an inactive pseudogene of each (c-Hras2 and c-Kras1) and the N-Ras gene.
  • Approximately one-half of follicular thyroid carcinomas have mutations in the Ras subfamily of oncogenes, most notably HRAS, NRAS, and KRAS.
  • On 27 September 2012, the FDA approved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, an anti-EGFR therapy.
  • The use of purine TINA-TFOs holds specific promise as antigene molecules toward the KRAS proto-oncogene.
  • Notable examples of potentially predictive cancer biomarkers include mutations on genes KRAS, p53, EGFR, erbB2 for colorectal, esophageal, liver, and pancreatic cancer; mutations of genes BRCA1 and BRCA2 for breast and ovarian cancer; abnormal methylation of tumor suppressor genes p16, CDKN2B, and p14ARF for brain cancer; hypermethylation of MYOD1, CDH1, and CDH13 for cervical cancer; and hypermethylation of p16, p14, and RB1, for oral cancer.
  • Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1, NCT01933932).
  • The magazine's contributor list includes Jason Lee Parry, Jonathan Leder, Matteo Montanari, Andrew Kuykendall, Ana Kras, Akila Berjaoui, and Quentin de Briey.
  • demonstrated superior detection of KRAS mutations in matched samples collected in both EDTA K3 and Streck BCT tubes.
  • KRAS mutations are associated with mucinous cysts, GNAS mutations are associated with IPMNs, CTNNB1 mutations are associated with solid pseudopapillary tumours.
  • HTI-1511 Anti-EGFR ADC: An antibody-drug conjugate (ADC) with a strong cytotoxin, monomethyl auristatin E, designed to treat EGFR-positive tumors, including those with KRAS and BRAF mutations.
  • HCT116 cells have a mutation in codon 13 of the KRAS proto-oncogene, and are suitable transfection targets for gene therapy research.
  • 3 shows the output of a search for PDX models whose engrafted tumors have amplified KRAS, the TP53 A159V mutation, a deletion of the ALB gene, and high KIT expression.
  • Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
  • Subsequently, many Russian leftists, including KRAS and RSD, accused the ACT of Ukrainian nationalism and Russophobia for a number of members of the organization pointing to Russia as the main culprit in the Russo-Ukrainian War and wishing it more defeat than "their" state.
  • In June 2024, the US FDA granted accelerated approval to adagrasib plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.



Search for KRAS in:






Page preparation took: 193.64 ms.